Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | MTOR | P42345 | 3/20 | 0.54 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.38 |
| ▸ | HPGD | P15428 | 10/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NT5E | P21589 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19003149 | 0.94 | PIK3CA (0.57) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL1113999 | 0.93 | PIK3CA (0.52) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL19003132 | 0.90 | PIK3CA (0.53) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL1113874 | 0.84 | PIK3CD (0.46) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL1113901 | 0.84 | MTOR (0.49) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL1114032 | 0.84 | PIK3CA (0.48) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL3423423 | 0.80 | PIK3CD (0.53) | PIK3CAPIK3CDCYP3A4PIK3CB | |
| SCHEMBL1114247 | 0.79 | PIK3CA (0.86) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL19003133 | 0.78 | PIK3CD (0.41) | PIK3CAMTORPIK3CDCYP3A4HDAC1 | |
| SCHEMBL25232626 | 0.77 | CYP3A4 (0.52) | PIK3CAMTORPIK3CDCYP3A4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279188-B1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-01-28 | — | — | EP | disclosed |
| EP-2279188-B1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-01-28 | — | — | EP | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445487-B2 | Purine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | CASTANEDO GEORGETTE (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158624-B2 | Purine PI3K inhibitor compounds and methods of use | GENETECH, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| EP-2279188-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009146406-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318411-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 75/4885PIK3CD 2/4885 |
| US-20120135988-A1 | PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CG | PIK3CA 1/4885MTOR 75/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.